Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01448824 · ClinicalTrials.gov registry record · Phase 1
A Study of LY2484595 on Pharmacokinetics in Healthy Participants
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 82
- Enrollment target
NCT01448824 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 82 participants.
The verdict
NCT01448824, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 82 participants
- Enrollment target
Study Summary
This is a 2-part study. Part 1 is to determine the safety and tolerability in healthy participants of increasing daily doses of LY2484595 for 14 days to achieve a blood level of LY2484595 much higher than what is needed for therapy. The amount of study drug that reaches the bloodstream and the time it takes for the body to get rid of it will be determined. The effect of the study drug on factors in the blood related to cholesterol will be measured. Part 2 is to determine how ketoconazole affects how much of the study drug, LY2484595, gets into the bloodstream and how long it takes to get rid of it. Information about any side effects that may occur will also be collected.
Interventions
- DRUG Placebo
- DRUG Ketoconazole
- DRUG LY2484595
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 82 participants |
| Start Date | 2011-10 |
| Est. Completion | 2012-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01448824
The ClinicalTrials.gov registry entry for NCT01448824 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 82 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01448824 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01448824 about?
NCT01448824 is a clinical study titled "A Study of LY2484595 on Pharmacokinetics in Healthy Participants". This is a 2-part study. Part 1 is to determine the safety and tolerability in healthy participants of increasing daily doses of LY2484595 for 14 days to achieve a blood level of LY2484595 much higher than what is needed for therapy. The amount of study drug that reaches the bloodstream and the time ...
What is the current status of trial NCT01448824?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 82 participants. The study started on 2011-10. Estimated completion is 2012-02.
What interventions are being tested in trial NCT01448824?
The interventions under investigation include: Placebo (DRUG), Ketoconazole (DRUG), LY2484595 (DRUG).
Who is sponsoring clinical trial NCT01448824?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.